Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis

NCT02289417 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02289417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02289417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
January 8, 2015
Completion date
June 3, 2019
Enrollment
170 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis